Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research note on Monday, December 23rd.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $4.35 on Monday. The firm has a market capitalization of $253.65 million, a P/E ratio of -15.54 and a beta of 0.77. Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The company’s fifty day moving average price is $4.79 and its 200-day moving average price is $5.02.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Vanda Pharmaceuticals by 26.8% in the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 5,459 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Vanda Pharmaceuticals by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company’s stock valued at $754,000 after purchasing an additional 22,249 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Vanda Pharmaceuticals by 8.8% in the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 4,449 shares in the last quarter. Barclays PLC grew its holdings in shares of Vanda Pharmaceuticals by 128.2% in the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after purchasing an additional 86,677 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock valued at $6,689,000 after purchasing an additional 94,870 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.